Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Vanda Pharmaceuticals Inc. (VNDA : NSDQ)

• Company Description    Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. Number of Employees: 278

• Price / Volume Information    Yesterday's Closing Price: $9.89 Daily Weekly Monthly 20 Day Moving Average: 590,424 shares Shares Outstanding: 56.49 (millions) Market Capitalization: $558.68 (millions) Beta: 0.59 52 Week High: $21.86 52 Week Low: $9.24 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.76% 2.76% 12 Week -22.31% -14.58% Year To Date -36.97% -22.98%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2200 PENNSYLVANIA AVE NW SUITE 300E - WASHINGTON,DC 20037 USA ph: 202-734-3400 fax: 202-296-1450 pr@vandapharma.com http://www.vandapharma.com

• General Corporate Information    Officers Mihael H. Polymeropoulos - President; Chief Executive Officer and Chairman Kevin Moran - Chief Financial Officer H. Thomas Watkins - Lead Independent Director Anne Sempowski Ward - Director Phaedra Chrousos - Director Peer Information Vanda Pharmaceuticals Inc. (CORR.) Vanda Pharmaceuticals Inc. (RSPI) Vanda Pharmaceuticals Inc. (CGXP) Vanda Pharmaceuticals Inc. (BGEN) Vanda Pharmaceuticals Inc. (GTBP) Vanda Pharmaceuticals Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 921659108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 07/27/22 Share - Related Items Shares Outstanding: 56.49 Most Recent Split Date: (:1) Beta: 0.59 Market Capitalization: $558.68 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.11 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.30 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/27/22

• Fundamental Ratios P/E Current FY Estimate: 32.97 Trailing 12 Months: 30.91 PEG Ratio: - Price Ratios Price/Book: 1.11 Price/Cash Flow: 14.64 Price / Sales: 2.10 EPS Growth vs. Year Ago Period: -173.33% vs. Previous Quarter: -191.67% Sales Growth vs. Year Ago Period: -3.95% vs. Previous Quarter: -11.51% ROE 03/31/22 - 3.65 12/31/21 - 6.81 09/30/21 - 7.23 ROA 03/31/22 - 3.08 12/31/21 - 5.80 09/30/21 - 6.16 Current Ratio 03/31/22 - 5.42 12/31/21 - 6.43 09/30/21 - 6.41 Quick Ratio 03/31/22 - 5.41 12/31/21 - 6.41 09/30/21 - 6.40 Operating Margin 03/31/22 - 6.79 12/31/21 - 12.34 09/30/21 - 12.77 Net Margin 03/31/22 - 6.79 12/31/21 - 12.34 09/30/21 - 12.77 Pre-Tax Margin 03/31/22 - 9.16 12/31/21 - 15.77 09/30/21 - 16.65 Book Value 03/31/22 - 8.89 12/31/21 - 9.06 09/30/21 - 8.85 Inventory Turnover 03/31/22 - 23.66 12/31/21 - 23.60 09/30/21 - 22.45 Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©